-
Addition of serplulimab to chemotherapy extends OS in small cell lung cancer
31 Jan 2023 00:54 GMT
… extensive-stage small cell lung cancer, according to randomized … for approximately 15% of lung cancer cases. Most patients present … extensive-stage small cell lung cancer. The analysis included … ), results showed a statistically significant improvement in OS …
-
How common is lung cancer?
30 Jan 2023 12:24 GMT
… of cancer.
While statistics show the number of lung cancer diagnoses, the … discusses the statistics for lung cancer, the prevalence of different types of lung cancer, lung cancer risk … working on compiling statistics for that year.
Lung cancer is the third …
-
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
27 Jan 2023 12:12 GMT
… non-small cell lung cancer following surgery and … endpoint, demonstrating a statistically significant improvement in … (ETOP).
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer …
-
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
27 Jan 2023 12:06 GMT
… non-small cell lung cancer following surgery and … endpoint, demonstrating a statistically significant improvement in … (ETOP).
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer …
-
FDA approves adjuvant Keytruda for non-small cell lung cancer
27 Jan 2023 04:12 GMT
… stage IIIA non-small cell lung cancer after resection and platinum-based … efficacy outcome. Results showed a statistically significant DFS improvement among the …
-
FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer
27 Jan 2023 00:31 GMT
… , or IIIA non-small cell lung cancer (NSCLC).
View full prescribing information … its primary endpoint, demonstrating a statistically significant improvement in DFS in …
-
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
25 Jan 2023 13:30 GMT
… AlloCAR T™ in small cell lung cancer (SCLC). The findings were … cancer - small cell - statistics. Cancer.Net. (2023, … 47;cancer-types/lung-cancer-small cell/statistics#:~:text=Lung%20cancer%20is%20the%20second,be%20diagnosed%20with%20lung%20cancer
-
Drug Therapeutics & Regulation in the U.S.
31 Jan 2023 16:02 GMT
… evidence linking cigarette smoking to lung cancer and emphysema inspired the development … edition of the Diagnostic and Statistical Manual which recognized Attention Deficit …
-
Microwave Ablation Market is expected to display a steady growth of 9.8% due to the Rise In Research & Development Activities Among Pharmaceutical Giants| UnivDatos Market Insights
31 Jan 2023 15:47 GMT
… the market growth. Furthermore, this statistical market research repository examines and … patients with primary or secondary lung cancers. It is anticipated that the …
-
Stage IIA Node-Negative NSCLC Patients: Outcomes after SBRT Vs. IMRT and 3DCRT
30 Jan 2023 22:19 GMT
… Node-Negative Non-Small Cell Lung Cancer > 5 cm” … stage IIA non-small cell lung cancer (NSCLC) tumors more than … in overall survival (OS), lung cancer-specific survival (LCSS), and … although the difference was not statistically significant (P=.37). Compared …
About
© 1995-2023